Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 22, 2023
Discovery & Translation
SIGLEC9 inhibition for glioblastoma; plus Long COVID genetic risks and more
BioCentury’s roundup of translational innovations
BioCentury | May 12, 2022
Deals
Cullinan gets $275M up front, reshapes deal with Taiho for EGFR program
Three years after sourcing targeted cancer program from Japanese pharma, Cullinan sells back subsidiary while retaining upside
BioCentury | Mar 30, 2022
Discovery & Translation
iPSC-derived NK cell therapies at AACR22
Presentations highlight gene edits and CAR engineering to improve efficacy of NK cell therapies
BioCentury | Apr 3, 2021
Product Development
Digging beyond the headlines at AACR 2021
Next-wave strategies for KRAS and TIGIT, allogeneic and personalized cell therapies, and targeted protein degraders
BioCentury | Jun 11, 2020
Deals
Cullinan adds first-in-class asset in hot NK cell checkpoint space
Via a deal with Avalon, Cullinan forms new single-asset unit with $26M series A to house anti-MICA mAb
BioCentury | Dec 27, 2019
Product Development
Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform
Xyphos’ animal data and focus on its CAR T switch platform paid off with Astellas takeout
BioCentury | Jul 19, 2019
Product Development
Why GammaDelta would do its Takeda build-to-buy all over again
How GammaDelta's 2017 $100 million option deal with Takeda fueled its multi-pronged pipeline strategy
BioCentury | Jun 8, 2018
Tools & Techniques
NK cell check-in
How new NK cell targets could lead to more powerful checkpoint inhibitors
Items per page:
1 - 10 of 17